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ABSTRACT: We performed replica exchange molecular
dynamics and forward ﬂux sampling simulations of hexapeptide
VQIINK and VQIVYK systems, also known as, respectively,
fragments PHF6* and PHF6 from the tau protein. Being a part
of the microtubule binding region, these fragments are known
to be aggregation prone, and at least one of them is a
prerequisite for ﬁbril formation of the tau protein. Using a
coarse-grained force ﬁeld, we establish the phase behavior of
both fragments, and investigate the nucleation kinetics for the
conversion into a β-sheet ﬁbril. As the conversion is, in
principle, a reversible process, we predict the rate constants for
both the ﬁbril formation and melting, and examine the
corresponding mechanisms. Our simulations indicate that,
while both fragments form disordered aggregates, only PHF6 is able to form β-sheet ﬁbrils. This observation provides a possible
explanation for the lack of available steric zipper crystal structures for PHF6*.
■ INTRODUCTION
Microtubule associated protein tau (MAPT), also known as tau,
is a natively unfolded protein1,2 involved in the regulation of
microtubule stability and therefore indirectly in the regulation
of intracellular microtubule networks in the central nervous
system.3−6 A repeat sequence, known as the microtubule
binding region (MTBR), along with the neighboring proline-
rich domain enables binding to microtubules.2,7−9 While tau is
largely hydrophilic in nature and soluble, hydrophobic motifs in
the MTBRs allow tau to form strong bonds with side chains of
tubulin, resulting in an increased stability of the microtubule.
Phosphorylation of tau lowers its aﬃnity to bind to
microtubules and therefore results in a loss of stability and
rigidity, while vice versa microtubule stabilization occurs due to
(partial) dephosphorylation of tau. While most tauopathies are
due to mutations,10 hyperphosphorylation of tau is observed in
many forms of dementia, causing a dramatic decrease in its
binding aﬃnity to microtubules.11,12 As a consequence, the
resulting pool of dissociated tau assembles into β-like structures
driven by hydrophobic interactions between the exposed
MTBRs.13 First, dimers and small soluble oligomers form,
which on their own display only little toxicity.14 As stacking
continues, however, bundles of tau interact and settle into
coiled-coil-like structures, so-called paired helical ﬁlaments
(PHFs), with widths varying between 10 and 20 nm.15
Eventually, PHFs stick together, forming neuroﬁbrilary tangles
(NFT), one of the distinctive hallmarks of Alzheimer’s
disease.16,17 However, while the extent of neurodegeneration
correlates with the presence of NFTs, it is still not clear what
speciﬁc process results in its neuronal toxicity and whether
NFTs play a leading role in this mechanism. Gaining an
understanding of tau−tau interplay and apprehending the
properties resulting in tau assembly might lead to insights
which can be used for the prevention of tau-induced toxicity in
Alzheimer’s and other tauopathies.
Previous research highlights two particular fragments,
VQIINK and VQIVYK in the MTBR repeats, respectively,
called PHF6* and PHF6, as key sequences in tau ﬁbrilization
and assembly18 (see Figure 1). It is suggested that these motifs
are notably prone to aggregate and that at least one of these
hexapeptide sequences is a prerequisite for tau oligomer
formation.19 Remarkably, only PHF6 seems to have an available
steric zipper crystal structure. In 2001, Bergen et al. proposed
two sequences containing these fragments as a subject for the
study of tau assembly, R2/wt and R3/wt, which can be used to
determine the eﬀect that the PHF fragments have as part of a
larger whole.20
Molecular simulation can complement experimental work by
giving detailed mechanistic insight into the aggregation process.
However, simulations are hampered by several obstacles. First,
system sizes are large, making the use of explicit force ﬁelds
expensive. Second, the force ﬁelds themselves are not well
suited for intrinsically disordered proteins. Third, the process of
aggregation and ﬁbrilization is a rare event that takes place on
the minute to hour time scale in vitro and on the year time scale
in vivo. Clearly, this puts stringent limitations on a
straightforward all-atom approach.
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adopt a comparable zipper because proline residues have a strong
tendency to disrupt β-sheets and break amyloid structures17
(Fig. 1a). Furthermore, an overlapping segment with the sequence
LDLSN in R2, which corresponds to amino acids 282–286,
bears the features of an amphiphilic amyloidogenic sequence
motif, whereas no additional sequences with these features are
found in R3 (ref. 18). This suggests that the potential to form a
second extended steric zipper interface is limited to the R2
segment, VQIINK.
Δk280 mutant. In the wild-type (WT) segment structure, interfaces
A and B are formed on opposite faces of the VQIINK β-sheet. It is
known that the ΔK280 mutation accelerates tau ﬁbre formation and
has been linked to tauopathies1,19. Lys280 lies at the junction
between interfaces A and B in our crystal structure (Fig. 1c,d) and
deleting K280 is expected to reverse the orientation of the
C-terminal residues by 180° about the β-strand axis20. The result
is to rotate the zipper-forming residues in interface B to the same
face of the β-sheet as interface A, merging the two separate
interfaces that lie on opposite faces in the WT to a single
extended zipper interface in the ΔK280 mutant (Fig. 1d, inset).
Modelling the steric zipper formed by the ΔK280 mutant shows
that the extended interface formed by these predicted structural
changes results in a longer zipper with a high Sc (0.77) and nearly
double the solvent-accessible surface area buried (Ab = 299 Å
2),
which explains how the ΔK280 mutant could promote a more-
rapid tau aggregation and toxicity.
VQIINK promotes rapid ﬁbre formation. Given the observation
that VQIINK forms a more-extensive steric zipper interface than
VQIVYK, we wondered if VQIINK would be a more-potent
driver of amyloid formation than VQIVYK. To test the
possibility, we replaced the residues VY in VQIVYK with IN,
which converts tau K18 into an engineered form that contains
two copies of VQIINK (named 2xIN). Similarly, 2xVY was
constructed and compared with WT K18 to determine how the
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Figure 1 | Atomic structures of amyloid ﬁbrils formed by segments of tau, viewed down the ﬁbril axes. a, Schematic of full-length tau showing the
positions of VQIINK and VQIVYK (coloured red) in the microtubule binding domain that contains four repeats (R1–R4), together termed K18. Shown below
is a sequence alignment of R2 and R3 from human tau with the VQIINK and VQIVYK segments underlined. b, Comparison of Ab and Sc for the VQIINK
(interface A (this paper)) and VQIVYK (ref. 10, PDB 2ON9) steric zippers. c, The two steric zipper interfaces, A and B, in the ten-residue KVQIINKKLD crystal,
shown as stick models with superimposed van der Waals atomic radii. The two interfaces have similar Ab and Sc. The numbering corresponds to the N- and
C-termini for the β-sheet coloured in cyan. d, Arrangement of interfaces A and B in the ten-residue WT KVQIINKKLD structure (left) and the predicted
arrangement in the ΔK280 mutant (centre and right). Trapezoids in the centre diagram represent steric zipper-forming residues that are predicted to line the
interface between the mated β-strands. The coloured arrows show the directions of the β-strands that form the steric zippers. Red, oxygen; blue, nitrogen;
green, main chain for A and C; cyan, main chain for B. In the WT structure, interfaces A (red) and B (blue) are formed on opposite faces of the VQIINK
β-sheet. Deletion of residue K280 is predicted to reverse the orientation of the C-terminal residues by 180° about the β-strand axes (centre) to merge steric
zipper interfaces A and B into a single extended steric zipper interface with greater Ab and Sc as calculated from the ΔK280 model (right and inset).
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the control crystals grew only after 8 months, suggesting that the
presence of DDNP is a catalyst for crystallization. The strongest
evidence supporting the presence of the small molecules in the
structure is provided by mass spectrometric analyses of the crystals.
The analyses also provided the reasoning for the undifferentiated
electron density, showing a very low molar abundance of both
Figure 2. Binding cavities of orange-G within fibers of the KLVFFA segment from Ab. Orange-G is bound internally to the steric zipper of
KLVFFA (residues 16–21 of Ab). It also contacts the lysine residues in the adjacent zipper. Peptide segments, forming b-sheet structures, are shown as
arrows and sticks, colored by atom type with carbons in white. Orange-G carbons are in orange for one molecule and brown for the other molecule.
Surface is shown for peptide atoms contacting the orange-G molecule with the orange carbons, shown as spheres. The view in (A) looks down the
fiber axis. The view in (B) is perpendicular to the fiber axis. Only side chains of interacting residues are shown. The area of the fiber buried by orange-G
(Methods) is 271 A˚2 and 272 A˚2 for the orange and brown colored orange-G, respectively, and is about 80% hydrophobic (contributed by the side
chains of Leu17, Val18, Phe19, and Phe20). The polar interactions are contributed by the charged side chains of Lys16. In (B), one of the b-sheets from
the adjacent pair and one orange-G molecule are removed for clarity.
doi:10.1371/journal.pbio.1001080.g002
Figure 3. Small molecule binding is specific for fiber polymorphism. Three forms of the KLVFFA segment from Ab (A–C) and the VQIVYK
segment from the tau protein (D–F) are presented. These forms serve as examples of packing polymorphism observed for amyloid fibrils [25]. The
view looks down the fiber axis; three layers of depth are depicted. The peptide segments and the small molecules are shown as sticks with non-
carbon atoms colored by atom type. In the KLVFFA forms (A–C), the anti-parallel strands (cartoon arrows) are alternately colored white and blue. The
VQIVYK forms (D–F) pack in parallel b-sheets (represented as cartoon arrows with white carbons). KLVFFA Form-1 (A) and Form-2 (B) (Colletier et al.
unpublished results) and VQIVYK Form-1 (D) [18] are tightly packed such that there are no voids to accommodate binding of small molecules. VQIVYK
Form-2 (E) [25] shows a shift in the steric zipper generating a void that can accommodate the binding of apolar molecules such as curcumin and
DDNP. A docked model of curcumin binding is shown (colored magenta) (Methods). Orange-G binds to unique forms of both KLVFFA and VQIVYK (C
and F), in which large voids are present in the crystal packing. In the KLVFFA complex (C), the binding is internal to the steric zipper, whereas in the
VQIVYK complex (F), the binding is between pairs of b-sheets, i.e., internal to bundles of protofilaments.
doi:10.1371/journal.pbio.1001080.g003
Towards a Pharmacophore for Amyloid
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Multiplicity of Ligand Binding 
sites in Tau Protofibrils
kcal/mol, suggesting that the dominant interaction is hydro-
phobic in nature. In the case of site 2, the residues GLU33,
VAL34, and LYS35 of fragment 2 contribute −2.0, −1.5, and
−1.5 kcal/mol, respectively, to the total binding free energy
based on the MM-GBSA approach, and in particular, the major
part of the contributions are due to van der Waals interaction.
In the case of site 3, GLN46, SER47, and LYS48 of fragment 3
dominantly contribute to the total interaction energies with
values for ΔERES as −2.0, −1.0, and −0.6 kcal/mol, respectively,
and the van der Waals interaction alone amounts to −2.2, −1.0,
and −1.6 kcal/mol, respectively. In the case of site 4, the
residues ARG44, VAL45, and GLN46 of fragment 4 contribute
with −1.9, −2.3, and −1.3 kcal/mol, respectively, and the same
residues of fragment 2 contribute with −2.5, −1.6, and −1.1
kcal/mol to the total interaction energies. As site 3 and site 4
are located next to each other, the residue GLN46 interacts
with the tracer in both sites. Again, the dominant part of the
interactions is due to the dispersion contribution, and it can be
clearly established that the hydrophobic−hydrophobic type
interaction is the driving orce for ﬁbril−tracer association. The
residues that dominantly contribute to the total interaction
energies for the PBB3 tracer−ﬁbril complex system are shown
in Figure 3, and in particular, the residues located in diﬀerent
binding sites are shown in diﬀerent colors. In the case of
FDDNP in site 1 of the tau ﬁbril, the dominantly contributing
residues are PRO59, ASN63, LYS64, and GLY62 of fragment 3,
and the contributions are −1.5, −1.3, −0.5, and −0.4 kcal/mol,
respectively. The van der Waals contributions alone are −1.4,
−0.9, −1.7, and −1.1 kcal/mol, suggesting that the hydro-
phobic interaction is dominantly contributing to the tracer
association with the tau ﬁbril. In contrast to the case of PBB3,
the FDDNP tracer does not strongly bind to site 4 (refer to
Figure 4).
In all of the above discussion, we are referring to binding
enthalpy as binding free energies with the assumption that the
entropic contributions might be less signiﬁcant in deciding the
relative binding aﬃnities. Moreover, it is generally assumed that
binding enthalpies are good estimates for the binding free
energies as the entropic contributions may not be binding site-
speciﬁc.31−34 In addition, the entropic calculations are
computationally very demanding. However, to check the
contributions to the binding free energy, we have computed
entropy using normal-mode analysis for FDDNP tracer in
diﬀerent binding sites of tau ﬁbril.35 The calculated values for
vibrational entropies were in the range of 2.8−6 kcal/mol,
which suggest that the vibrational contributions in fact favor the
complex formation. The contributions were 2.8, 4.8, 5.8, and
6.0 kcal/mol for sites 1, 2, 3, and 4, respectively. As we see here,
the entropic contributions are to some extent site-speciﬁc. In
addition, it also can be deduced that if the diﬀerence in entropic
contributions for a tracer in diﬀerent sites exceeds the
diﬀerence in binding enthalpies, then the preference to sites
can be switched. However, as can be seen from Table 2, the
binding enthalpy values for most of the tracers in diﬀerent sites
are well-separated, suggesting that the discussion on relative
binding aﬃnities based on binding enthalpies is still valid.
In order to further validate the results obtained from the
force-ﬁeld MM-GBSA approach, we have also calculated the
interaction energies using density functional theory (DFT)
between the ligand−amino acid residues that contribute
signiﬁcantly to the total binding free energies. The calculated
interaction energies between the PBB3 tracer and the residues
44, 45, and 46 of the fourth fragment are −5.22, −5.07, and
−0.22 kcal/mol, while the interaction energies computed
between the ligand and the residues 44, 45, and 46 of the
second fragment are −8.08, −0.08, and −1.93 kcal/mol,
respectively. In agreement with the force-ﬁeld approach, this
cluster of residues is contributing to almost −10 kcal/mol
interaction energy between the tracer and residue. Diﬀerences
are realized if we look at individual contributions from each
residue, but this can be explained. The interaction energies
Figure 3. Residues of sites 1−4 contributing to the interaction
energies dominantly in tau protoﬁbril.
Figure 4. Decomposition analysis of free energy of binding for
FDDNP with tau ﬁbril.
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PET imaging tracers
Integrative Modeling of Tau 
anti-aggregation agents 
• QSAR modeling  
• inference of molecular properties associated with activity (IC50)

• inference of molecular properties associated with cytotoxicity (Log (LDH%) )

• Docking calculations 

• binding modes of more active/less active compounds on PHF8 dimers

• rebuilding of PHF8 tetramers from dimers of PHF8 docked complexes

• MD simulations 
• docking poses as initial configurations for simulations

• evaluation of binding modes and stoichiometry (compound/PHF6 tetramer)
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Rhodanine-Based Tau Aggregation Inhibitors in Cell Models of
Tauopathy**
Bruno Bulic, Marcus Pickhardt, Inna Khlistunova, Jacek Biernat, Eva-Maria Mandelkow,
Eckhard Mandelkow,* and Herbert Waldmann*
The two histopathological hallmarks that characterize Alz-
heimer!s disease (AD) are the extracellular amyloid plaques
that are formed by b-amyloid fragments of the amyloid
precursor protein (APP), and intracellular neurofibrillary
tangles and neuropil threads, which consist of the micro-
tubule-associated protein tau forming paired helical filaments
with highly ordered structures, as recently corroborated by X-
ray microcrystallography.[1] In addition, tau deposits similar to
those of AD occur in several “tauopathies”.[2,3] The normal
function of tau is to stabilize the microtubule network for the
transport of vesicles and organelles in nerve cells, which is
necessary for the communication between cells and thus for
brain activity. When tau aggregates, it is thought that the
tracks for transport (microtubules) break down and the
transport is interrupted.[4–6] Moreover, the relevance of tau for
neurodegeneration induced by b amyloid has been demon-
strated in a mouse model.[7,8] It would therefore be highly
desirable to find methods to keep tau in a functional state and
prevent or reverse abnormal aggregation. The quest for cures
for Alzheimer!s disease is very intense. Available therapies to
date make use of cholinesterase inhibitors and NMDA
receptor antagonists,[9,10] and newer approaches focus, for
example, on inhibition of tau phosphorylation and amino-
peptidase activation.[11–14]
Thus, the development of tau aggregation inhibitors that
are also able to disaggregate filaments could provide an
alternative to existing strategies.[15–18] Herein we report the
investigation of substituted rhodanines with these properties
in vitro and in a cell model consisting of a neuroblastoma cell
line that expresses tau in an inducible fashion with subsequent
aggregation. In an initial high-throughput screen,[19,20] several
aggregation inhibitors were identified. From these hits,
rhodanines (2-thioxothiazolidin-4-ones, Figure 1a) were
selected for synthesis of a collection because of their activity
in the screening and because the rhodanine core in general
has been shown to be a viable scaffold for the development of
biologically active molecules. Thus, rhodanines are classified
as nonmutagenic,[21] and a long-term study on the clinical
effects of the rhodanine-based Epalrestat demonstrated that
it is well tolerated.[22] Several assays were performed to
develop compounds that would show strong effects on the
assembly and disassembly of paired helical filaments (char-
acterized by their IC50 and DC50 values, corresponding to the
half maximal compound concentration necessary for inhib-
ition of tau assembly into aggregates and disassembly of
preformed filament aggregates, respectively). We performed
a tau aggregation assay in vitro based on the fluorescence
change of the aggregate-specific stain thioflavin S (ThS) as a
readout and using the three-repeat tau construct K19 derived
from the fetal isoform htau23[19,23] (see the Supporting
Information). In addition, we investigated the aggregation
of the four-repeat construct K18, either with the wild-type
sequence, or with two types of mutations. In the “proaggre-
gation” mutant K18DK280, the absence of K280 strongly
enhances aggregation.[24] The opposite behavior is observed
with the “antiaggregation” mutant by the insertion of pro-
lines, which act as breakers of b structure and thus prevent
aggregation (I277P, I308P).[25]
Figure 1. Variation of inhibitor structure. a) Structure of the hit com-
pound. Variations of flanking regions of the central rhodanine core
(part B) are possible in parts A and C. b) Variations of the core (R1 and
R2) and on the flanking substituents (R3 and R4).
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For the synthesis of a compound collection we employed
an iterative approach and focused on the heterocycle as well
as its substituents. Initial attempts focused on immobilization
of an N-carboxyalkyl-substituted rhodanine core on a poly-
meric resin by means of an ester bond, and subsequent
Knoevenagel reaction with aromatic aldehydes equipped with
a suitable functional group to allow formation of the biaryl
bond by means of a Pd0-catalyzed aryl coupling reaction.
However, these attempts failed because the Pd0-catalyzed
reaction was inhibited by the rhodanine heterocycle. Thus, the
solution-phase synthesis sequence shown in Scheme 1 was
employed; this sequence involves formation of biaryl ald -
hydes and subsequent Kn evenagel condensation with the
rhodanine core as key steps (for a solid-phase synthesis of
rhodanin s by a different strategy, see referenc [28]). The
a yl aldehydes necessary for the Knoevenagel condensation
(pa t C, Figure 1a) were obtained by Suzuki coupling
between haloaromatics and functionalized boronic acids
(Scheme 1).
Initially, w focused on the ce tral heterocycle itself,
r placing the original rhodanine core with ther heterocycles
(R1 and R2, Figure 1b). In these experiments, rhodanines
(R1=S and R2= S), thiohydantoin (R1= S and R2=N),
thioxooxazolidine (R1= S and R2=O), oxazolidinedione
(R1=O and R2=O), and hydantoin (R1=O and R2=N)
were employed (see the Supporting Information) and the
following trend in inhibition of tau aggregation was observed:
rhodanine (1)> thiohydantoin (3)@ oxazolidinedione (7)>
thioxooxazolidinone (9)> hy antoin (10). The rhodanine
heterocycle appeared to be the most potent. The thioxo
group in rhodanines is known as a carb xylic acid bioisoster
by size, low electronegativity, and ability to build hydrogen
bonds.[26,27] On the basis of these observations, the rhodanine
heterocycle was kept, and substituents A and C were varied
(Figure 1a).
We investigated the importance of the carboxylic acid (A,
Figure 1a) and the influence of the substitution and length of
the linker connecting the central core (B, Figure 1a) to the
carboxylic acid (Figure 2). Replacement of the carboxylic
acid with an imidazole or a benzimidazole as well as
esterification led to reduced disassembly activity (Table 1,
entries 1–4). Furthermore, the length of the linker between
the carboxylic acid and the rhodanine core (B, Figure 1a) was
varied. These experiments revealed that increasing the
distance up to two carbon
bonds resulted in an appre-
ciable increase in the com-
pound!s inhibitory potency
without markedly affecting
the disassembly activity
(Table 1, entries 1, 5, and
6). In subsequent experi-
ments, biaryl part C of the
compounds (Figure 1a)
was varied. The heteroaro-
matic side chain (part C,
Figure 1a) tolerated varia-
tions, but modifications on
the furan heterocycle led
to reduced potency
(Table 1, entries 1, 5, and
7–9, and the Supporting
Information), probably as
a result of both electronic
and steric changes, as
replacement of the furan
ring in 16 for thiophene in
22 reduced the potency.
Very bulky substitu nts,
such as adamantyl or fer-
rocene (Table 1, entries 10 and 11), at the end of side chain C
were generally well tolerated, reducing the overall efficiency
of the compounds only slightly. Also, introduction of a
charged group by means of a carboxylic acid did not influence
the potency considerably (Table 1, entries 12–14), underlining
the structural flexibility around this position.
After completing the synthesis of our focused library, we
ob erv d that the efficiency of the most potent d rivatives are
in the nano olar range for both inhibition and disaggrega ion
(19, IC50= 0.17 mm, DC50= 0.13 mm, Table 1). Examples of
dose–response curves are shown in Figu 3, both f r the
Scheme 1. Synthesis of a compound collection. Reagents: a) 5 mol% [PdCl2(PPh3)2] , 2m aq Na2CO3, 1,2-
dimethoxyethane, 85 8C, 9 h. b) Ethyl isothiocyanatoacetate, Et3N, toluene, reflux, 4 h. c) Bis(carboxymethyl)tri-
thiocarbonate, Na2CO3, iPrOH, reflux, 18 h. d) Bis(p-nitrophenyl)carbonate, Et3N, N,N-dimethylformamide,
room temperature, 12 h then HCl aq, dioxane, reflux, 2 h. e) For R2=O, NH: NaOAc, dioxane, 90 8C, 2 h; for
R2=S: piperidine, CH2Cl2, room temperature, 12 h. f) NaOH, dioxane/water, room temperature, 1 h. g)meta-
Chloroperoxybenzoic acid, NaHCO3, CH2Cl2, room temperature, 24 h.
Figure 2. Structure–activity relationship.
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concentration used in the cellular screen), revealed that
tubulin polymerization is at most only marginally affected by
the rhodanines. In this established assay, tubulin at 30 mm
without tau served as a negative control because it is unable
to self-assemble into microtubules below the critical concen-
tration. In the presence of tau (10 mm), tubulin polymerizes
within 4 minutes (Figure 6).[19]
Taken together, these results demonstrate that the rho-
danines investigated by us inhibit tau aggregation and most
importantly promote paired helical filament disassembly at
100–600 nm concentration. They also display activity in
cellular assays without showing cytotoxicity (at the concen-
tration investigated) or interference with the normal function
Figure 3. Dose–response curves. a) Inhibition of tau aggregation by
rhodanine-derived compounds. The extent of aggregation is measured
by ThS fluorescence and plotted as a percentage of the untreated
control. The black line represents the initial hit structure 1. b) Dose–
response curves for disassembly of preformed PHFs by rhodanine-
derived compounds.
Figure 4. Electron micrographs of K19 PHFs treated with different
concentrations of 30 and 50 for 12 h at 37 8C, showing the breakdown
of PHFs into smaller fragments for compound 30. Inactive compound
50 was used for a negative control. The methods used are described
elsewhere.[6]
Figure 5. Cell assay of aggregation inhibitors. Expression of K18DK280
tau in doxycyclin-inducible N2a cells leads to aggregate formation,
which is inhibited by rhodanines. Cells were stained with aggregate-
specific thioflavine-S (green, center column) and with tau antibody
K9JA (red, left column). Compounds 30 and 14 were applied for 5 days
at 15 mm (top row, without inhibitor; middle row, with 30 ; bottom row,
with 14). Note the disappearance of the ThS stain relative to the
control without compound (“DMSO”). Scale bar: 20 mm.
Figure 6. Rhodanines have only a minor effect on tau-induced micro-
tubule assembly. Tubulin dimer (30 mm) was incubated with hTau40wt
(10 mm) in the presence or absence of rhodanine compounds (60 mm).
Samples were incubated in a microtiter plate at 37 8C, and absorption
was measured continuously at 350 nm and plotted versus time.
Tubulin aloneg, tubulin and hTau40wtl, rhodanine 14c*,
and rhodanine 30c~.
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dissolution of PHFs (EM)
inhibition of aggregation (Figure 3a) and for the dissolution
of preformed paired helical filaments (PHFs; Figure 3b).
The curves exhibit the typical sigmoidal decrease of
aggregated protein at increasing compound concentrations.
Figure 4 illustrates examples of
PHFs, made from the construct
K19, in the process of disassembly
after incubation overnight with
increasing inhibitor concentrations
of 30. Filaments are seen in various
stages of shortening or breaking
and reveal a concentration-depen-
dent degree of dissolution.
The compounds were investi-
gated in murine neuroblastoma
N2a cells to determine whether
they are also active in cellular
systems. In these experiments, tau
expression was induced by incuba-
tion with doxycyclin. The results
shown in Figure 5 were obtained by
switching on the tau expression by
doxycyclin, incubating the cells with
compound (15 mm), and scoring for
ThS fluorescence after 5 days. To
assess the depolymerization of pre-
formed aggregates, the expression
of tau was induced for 5 days, then
compounds were added, and the
level of ThS fluorescence was mea-
sured after 2 more days. In these
experiments the compounds were
applied in 15 mm concentration
because they were not cytotoxic to
the cells at this concentration (see
below).
To exclude that the cell assay
results might be impaired by poten-
tial cytotoxicity of the aggregation
inhibitors, all compounds were
assayed for cytotoxicity at 10 mm
concentration. Orientating experi-
ments employed an established lac-
tate dehydrogenase assay (LDH),
which reports on the leakiness of
membranes in degenerating cells.
After the cells were incubated for
24 hours with 10 mm compound, the
degree of cell lysis was determined
by LDH release. The assay revealed
that the compounds are not or at
worst only very weakly cytotoxic
(see the Supporting
Information).[19,29] Furthermore, we
investigated whether some of the
most potent compounds interfere
with the physiological function of
tau, that is, binding to microtubules.
An in vitro assay of tubulin poly-
merization in the presence or absence of 14 and 30, which
showed the highest activity in the cellular assay (inhibition of
ca. 70% of the aggregation relative to the untreated control)
and a concentration of 60 mm (i.e. four times higher than the
Table 1: Compound structures, IC50 and DC50 values, PHF inhibition in cells, and cytotoxicity.
Entry Compd R3[a] R4[a] IC50 [mm]
[b] DC50 [mm]
[b] Inhibition in
cells[c] [%]
1 1 0.82 0.10 20.40!5.37
2 4 4.36 1.80 n.d.
3 14 0.67 0.94 70.47!4.49
4 49 1.09 0.80 n.d.
5 16 0.47 0.30 21.55!13.82
6 23 1.22 1.04 n.d.
7 22 0.97 0.77 n.d.
8 27 5.03 1.66 n.d.
9 42 7.92 1.40 n.d.
10 44 0.69 0.42 n.d.
11 54 0.37 0.47 n.d.
12 33 0.58 0.52 n.d.
13 34 0.73 0.60 n.d.
14 35 0.78 0.58 n.d.
15 30 0.26 0.16 69.02!3.10
16 17 0.54 0.39 62.67!4.08
17 19 0.17 0.13 16.49!4.38
[a] Substituents R3 and R4 refer to Figure 1b (R1=R2=S). [b] The IC50 and DC50 values represent the
assembly-inhibition and disassembly-inducing half-maximal concentrations, respectively, measured
in vitro. For each data point, experiments were performed in triplicate and averaged. The standard error
of the IC50 or DC50 values determined from the curves was 10–20%. [c] The values obtained by
incubating the cells with 15 mm compound correspond to the level of inhibition of tau aggregation
normalized to a control without inhibitor (0%) in cells. n.d.: not determined.
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QSAR Study of Rhodanines: 
activity & cytotoxicity
inhibition of aggregation (Figure 3a) and for the dissolution
of preformed paired helical filaments (PHFs; Figure 3b).
The curves exhibit the typical sigmoidal decrease of
aggregated protein at increasing compound concentrations.
Figure 4 illustrates examples of
PHFs, made from the construct
K19, in the process of disassembly
after incubation overnight with
increasing inhibitor concentrations
of 30. Filaments are seen in various
stages of shortening or breaking
and reveal a concentration-depen-
dent degree of dissolution.
The compounds were investi-
gated in murine neuroblastoma
N2a cells to determine whether
they are also active in cellular
systems. In these experiments, tau
expression was induced by incuba-
tion with doxycyclin. The results
shown in Figure 5 were obtained by
switching on the tau expression by
doxycyclin, incubating the cells with
compound (15 mm), and scoring for
ThS fluorescence after 5 days. To
assess the depolymerization of pre-
formed aggregates, the expre sion
of tau was induced for 5 days, then
compounds were added, a d he
level of ThS fluorescenc was mea-
sured after 2 more days. In these
experiments the compounds were
applied in 15 mm concentration
because they were not cytotoxic to
the cells at this concentration (see
below).
To exclude that the cell assay
results might be impaired by poten-
tial cytotoxicity of the aggregation
inhibitors, all compounds were
assayed for cytotoxicity at 10 mm
concentration. Orientating experi-
ments employed an established lac-
tate dehydrogenase assay (LDH),
which reports on the leakiness of
membranes in degenerating cells.
After the cells were incubated for
24 hours with 10 mm compound, the
degree of cell lysis was determined
by LDH release. The assay revealed
that the compounds are not or at
worst only very weakly cytotoxic
(see the Supporting
Information).[19,29] Furthermore, we
investigated whether some of the
most potent compounds interfere
with the physiological function of
tau, that is, binding to microtubules.
An in vitro assay of tubulin poly-
merization in the presence or absence of 14 and 30, which
showed the highest activity in the cellular assay (inhibition of
ca. 70% of the aggregation relative to the untreated control)
and a concentration of 60 mm (i.e. four times higher than the
Table 1: Compound structures, IC50 and DC50 values, PHF inhibition in cells, and cytotoxicity.
Entry Compd R3[a] R4[a] IC50 [mm]
[b] DC50 [mm]
[b] Inhibition in
cells[c] [%]
1 1 0.82 0.10 20.40!5.37
2 4 4.36 1.80 n.d.
3 14 0.67 0.94 70.47!4.49
4 49 1.09 0.80 n.d.
5 16 0.47 0.30 21.55!13.82
6 23 1.22 1.04 n.d.
7 22 0.97 0.77 n.d.
8 27 5.03 1.66 n.d.
9 42 7.92 1.40 n.d.
10 44 0.69 0.42 n.d.
11 54 0.37 0.47 n.d.
12 33 0.58 0.52 n.d.
13 34 0.73 0.60 n.d.
14 35 0.78 0.58 n.d.
15 30 0.26 0.16 69.02!3.10
16 17 0.54 0.39 62.67!4.08
17 19 0.17 0.13 16.49!4.38
[a] Substituents R3 and R4 refer to Figure 1b (R1=R2=S). [b] The IC50 and DC50 values represent the
assembly-inhibition and disassembly-inducing half-maximal concentrations, respectively, measured
in vitro. For each data point, experiments were performed in triplicate and averaged. The standard error
of the IC50 or DC50 values determined from the curves was 10–20%. [c] The values obtained by
incubating the cells with 15 mm compound correspond to the level of inhibition of tau aggregation
normalized to a control without inhibitor (0%) in cells. n.d.: not determined.
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QSAR model of Rhodanine 
derivatives
For the synthesis of a compound collection we employed
an iterative approach and focused on the heterocycle as well
as its substituents. Initial attempts focused on immobilization
of an N-carboxyalkyl-substituted rhodanine core on a poly-
meric resin by means of an ester bond, and subsequent
Knoevenagel reaction with aromatic aldehydes equipped with
a suitable functional group to allow formation of the biaryl
bond by means of a Pd0-catalyzed aryl coupling reaction.
However, these attempts failed because the Pd0-catalyzed
reaction was inhibited by the rhodanine heterocycle. Thus, the
solution-phase synthesis sequence shown in Scheme 1 was
employed; this sequence involves formation of biaryl alde-
hydes and subsequent Knoevenagel condensation with the
rhodanine core as key steps (for a solid-phase synthesis of
rhodanines by a different strategy, see reference [28]). The
aryl aldehydes necessary for the Knoevenagel condensation
(part C, Figure 1a) were obtained by Suzuki coupling
between haloaromatics and functionalized boronic acids
(Scheme 1).
Initially, we focused on the central heterocycle itself,
replacing the original rhodanine core with other heterocycles
(R1 and R2, Figure 1b). In these experiments, rhodanines
(R1=S and R2= S), thiohydantoin (R1= S and R2=N),
thioxooxazolidine (R1= S and R2=O), oxazolidinedione
(R1=O and R2=O), and hydantoin (R1=O and R2=N)
were employed (see the Supporting Information) and the
following trend in inhibition of tau aggregation was observed:
rhodanine (1)> thiohydantoin (3)@ oxazolidinedione (7)>
thioxooxazolidinone (9)> hydantoin (10). The rhodanine
heterocycle appeared to be the most potent. The thioxo
group in rhodanines is known as a carboxylic acid bioisoster
by size, low electronegativity, and ability to build hydrogen
bonds.[26,27] On the basis of these observations, the rhodanine
heterocycle was kept, and substituents A and C were varied
(Figure 1a).
We investigated the importance of the carboxylic acid (A,
Figure 1a) and the influence of the substitution and length of
the linker connecting the central core (B, Figure 1a) to the
carboxylic acid (Figure 2). Replacement of the carboxylic
acid with an imidazole or a benzimidazole as well as
esterification led to reduced disassembly activity (Table 1,
entries 1–4). Furthermore, the length of the linker between
the carboxylic acid and the rhodanine core (B, Figure 1a) was
varied. These experiments revealed that increasing the
distance up to two carbon
bonds resulted in an appre-
ciable increase in the com-
pound!s inhibitory potency
without markedly affecting
the disassembly activity
(Table 1, entries 1, 5, and
6). In subsequent experi-
ments, biaryl part C of the
compounds (Figure 1a)
was varied. The heteroaro-
matic side chain (part C,
Figure 1a) tolerated varia-
tions, but modifications on
the furan heterocycle led
to reduced potency
(Table 1, entries 1, 5, and
7–9, and the Supporting
Information), probably as
a result of both electronic
and steric changes, as
replacement of the furan
ring in 16 for thiophene in
22 reduced the potency.
Very bulky substituents,
such as adamantyl or fer-
rocene (Table 1, entries 10 and 11), at the end of side chain C
were generally well tolerated, reducing the overall efficiency
of the compounds only slightly. Also, introduction of a
charged group by means of a carboxylic acid did not influence
the potency considerably (Table 1, entries 12–14), underlining
the structural flexibility around this position.
After completing the synthesis of our focused library, we
observed that the efficiency of the most potent derivatives are
in the nanomolar range for both inhibition and disaggregation
(19, IC50= 0.17 mm, DC50= 0.13 mm, Table 1). Examples of
dose–response curves are shown in Figure 3, both for the
Scheme 1. Synthesis of a compound collection. Reagents: a) 5 mol% [PdCl2(PPh3)2] , 2m aq Na2CO3, 1,2-
dimethoxyethane, 85 8C, 9 h. b) Ethyl isothiocyanatoacetate, Et3N, toluene, reflux, 4 h. c) Bis(carboxymethyl)tri-
thiocarbonate, Na2CO3, iPrOH, reflux, 18 h. d) Bis(p-nitrophenyl)carbonate, Et3N, N,N-dimethylformamide,
room temperature, 12 h then HCl aq, dioxane, reflux, 2 h. e) For R2=O, NH: NaOAc, dioxane, 90 8C, 2 h; for
R2=S: piperidine, CH2Cl2, room temperature, 12 h. f) NaOH, dioxane/water, room temperature, 1 h. g)meta-
Chloroperoxybenzoic acid, NaHCO3, CH2Cl2, room temperature, 24 h.
Figure 2. Structure–activity relationship.
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pIC50 = -1.14MR +45.43HOMO +0.14µ -3.24q4 +16.58
n=35; R2= 0.81; s=0.33; F=15.99; q2 =0.60; p<0.01
Test set: n=9; R2= 0.60; =0.57; F=5.86
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Metrics for MD analysis
• native contacts

• radius of gyration

• low frequency motions (PCA analysis)

• conformational flexibility (protein alphabet)
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Fraction of native contacts 
and radius of gyration
• native contacts are calculated for residues whose 
distance (Å) is smaller than the number specified in 
‘Distance cutoﬀ’ (default: 8Å) , and which are at least as 
many residues apart as the number specified in ‘Residue 
separation’ (default: 2). 

• mass-weighted radius of gyration of the selected atoms 
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500ns
Conclusions
• loss of native contacts

• destabilisation of C-terminus

• transitions with increase of radius of gyration

• sizzling motion in anti-parallel dimers

• binding modes with shifting one (parallel) β-strand dimer

• stoichiometry 2:1 may facilitate inter-dimer insertion 
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